Pathways to Alzheimer's disease

• Recent trials of anti-amyloid agents have not produced convincing improvements in clinical outcome in Alzheimer's disease; however, the reason for these poor or inconclusive results remains unclear. Recent genetic data continue to support the amyloid hypothesis of Alzheimer's disease with protective variants being found in the amyloid gene and both common low-risk and rare high-risk variants for disease being discovered in genes that are part of the amyloid response pathways. These data support the view that genetic variability in how the brain responds to amyloid deposition is a potential therapeutic target for the disease, and are consistent with the notion that anti-amyloid therapies should be initiated early in the disease process. © 2014 The Association for the Publication of the Journal of Internal Medicine.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

Alzheimer's disease

Amyloid

Cell biology

Genetics

Tau

amyloid precursor protein

apolipoprotein E

avagacestat

bapineuzumab

clusterin

gamma secretase inhibitor

immunoglobulin G1 antibody

Notch3 receptor

presenilin

semagacestat

solanezumab

Alzheimer disease

article

cellular distribution

cerebrospinal fluid level

cholesterol metabolism

cholesterol synthesis

cholesterol transport

clinical pathway

complement classical pathway

drug clearance

follow up

genetic analysis

genetic association

genetic variability

innate immunity

nonhuman

pathogenesis

phase 1 clinical trial (topic)

phase 2 clinical trial (topic)

phase 3 clinical trial (topic)

priority journal

randomized controlled trial (topic)

risk factor

signal transduction

Amyloid beta-Peptides

Brain

Early Medical Intervention

Genetic Predisposition to Disease

Humans

Immunotherapy

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)